Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer|Node-negative Breast Cancer|Breast Carcinoma
Interventions: DRUG: Anastrozole 1mg|DRUG: Letrozole 2.5mg|DRUG: Exemestane 25 mg|DRUG: Tamoxifen
Sponsor: Veronica Morgan Jones